+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 24 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of azenosertib ZN-c3, an oral selective WEE1 inhibitor, in women with platinum-resistant, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. This Phase 2 study focuses on patients whose tumors express Cyclin E1 protein, identified through a specialized assay. The study includes multiple parts, with Part 2 specifically enrolling Cyclin E1 positive patients to better understand the drugs impact in this subgroup. Participants receive azenosertib orally, following an intermittent dosing schedule of 400 mg once daily for 5 days, then 2 days off. Different dosing arms exist, including a 300 mg dose, all administered under careful monitoring. The study is randomized and open-label, with several parts completed and Part 2c actively enrolling. The treatment period and follow-up extend for up to approximately 12 months to assess various outcomes. During the study, participants undergo tumor testing, disease evaluation by standard imaging criteria RECIST v1.1, and monitoring of blood markers such as CA-125. Researchers track response rates, duration of response, progression-free survival, clinical benefit, and adverse events. Regular assessments ensure safety and treatment adherence. The total participation duration encompasses treatment and follow-up phases, with outcomes measured up to about one year after the last participant enrolls.

Age: 18Years +FEMALEPhase 2
89 locations
P

Actively Recruiting

Researchers are evaluating disitamab vedotin alone or combined with pembrolizumab to treat urothelial cancer that expresses HER2. This study focuses on participants with locally advanced or metastatic urothelial cancer that cannot be removed by surgery. It aims to assess how well the drug works and to monitor the side effects experienced by participants. Participants receive disitamab vedotin intravenously every 2 weeks, either alone or with pembrolizumab given by intravenous infusion on Day 1 of each 6-week cycle. The study includes multiple cohorts receiving different combinations or monotherapy treatments. The treatment period and monitoring last approximately 2 years, with ongoing assessments of drug effects and safety. During the study, participants undergo regular evaluations including imaging scans to measure tumor response, laboratory tests, electrocardiograms to monitor heart function, and assessments of side effects. Researchers measure treatment response using established cancer evaluation criteria and track survival and disease control over about 3 years. Participants are closely monitored for adverse effects and blood levels of the drugs to understand how the treatments behave in the body.

Age: 18Years +All GendersPhase 2
221 locations
E

Actively Recruiting

Alzheimers disease is a progressive and irreversible brain disorder that commonly causes dementia in older adults. It begins with mild memory problems such as misplacing items or forgetting events and can worsen to confusion, agitation, and loss of independence. This research aims to test the safety, effects, and how the body processes ABBV-1758, an investigational drug being studied for Alzheimers disease in a multi-stage clinical trial. Participants receive ABBV-1758 or a placebo through intravenous or subcutaneous injections once every four weeks for 24 weeks. The study includes three stages Stage A with multiple dose levels using a 41 randomization, Stage B expanding dosing cohorts, and Stage C enrolling Japanese and Chinese participants with the same randomization. After treatment, participants are followed for 12 weeks and may join a blinded 12-month extension depending on amyloid PET scan results. During the study, participants attend regular clinic visits for medical assessments, blood tests, and questionnaires to monitor safety and effects. Researchers measure outcomes like adverse events, lab test changes, brain amyloid levels, and drug concentration in the blood over approximately 40 weeks. The total participation time includes treatment, follow-up, and possible extension periods.

Age: 50Years - 90YearsAll GendersPhase 1Phase 2
13 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.

Age: 55Years - 90YearsAll GendersPhase 3
296 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in treating cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3 study is randomized, double-blind, and placebo-controlled, aiming to improve thinking abilities measured by specific standardized assessments. Participants will receive either KarXT plus KarX-EC or a placebo at specified doses on designated days. The study lasts 24 weeks, during which outcomes like changes in cognitive function, daily living activities, and behavioral symptoms will be assessed. The trial includes an active comparison group and a placebo group to evaluate treatment effects. Throughout the study, participants and their caregivers will attend regular visits for clinical assessments, including cognitive tests ADAS-Cog11, caregiver interviews, and monitoring of adverse events and vital signs. Researchers will carefully track safety and treatment response over the 24-week period to understand the impact of the study drugs on Alzheimers symptoms.

Age: 60Years - 85YearsAll GendersPhase 3
128 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of adding the drug tirzepatide to ongoing ixekizumab therapy in adults with moderate-to-severe plaque psoriasis who are also overweight or obese with at least one weight-related health condition. This Phase 4 study aims to assess how well this combination works in real-world clinical practice over a period of up to 12 months. Participants will continue their prescribed ixekizumab treatment and start taking tirzepatide through subcutaneous injections according to approved guidelines. The study is designed as a single-arm, open-label trial where all participants receive tirzepatide along with ixekizumab. The treatment period covers about one year, during which the response to this combined therapy will be closely observed. Throughout the study, participants will undergo regular assessments to measure improvements in their skin condition and weight. Key outcomes include the percentage achieving minimal impact on quality of life related to dermatology and at least 10% weight loss after 12 months. Additional evaluations at 6 and 12 months will monitor skin involvement, global physician and patient assessments, and weight changes. Safety and tolerability will also be followed during this time.

Age: 18Years +All GendersPhase 4
38 locations
T

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.

Age: 18Years +All GendersPhase 3
594 locations
E

Actively Recruiting

Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.

Age: 18Years +All GendersPhase 3
671 locations
O

Actively Recruiting

This trial is for patients with hypertension who have completed previous QCZ484 studies. It aims to gather more information on the long-term safety and effectiveness of QCZ484, a treatment given to lower high blood pressure. The study is an extension phase to build on prior research results for hypertensive patients who successfully finished earlier treatment periods. Participants in this open-label extension study will receive QCZ484 by subcutaneous injection every six months. This single-group, multicenter study offers enrollment to patients at the month 12 visit of their parent study, provided they meet eligibility and have completed their prior treatment safely. The treatment continues to be monitored for up to 66 months to assess ongoing effects and tolerability. During the study, participants will have regular assessments including ambulatory and office blood pressure measurements at baseline and throughout the extension period. Safety will be closely monitored by tracking any adverse events up to 66 months. The study collects data on blood pressure changes and side effects to understand how well QCZ484 works and how safe it remains over the long term. Participation involves scheduled visits aligned with the injection schedule and ongoing health evaluations.

Age: 18Years +All GendersPhase 2
25 locations
R

Actively Recruiting

Researchers are evaluating AV-1980R, an investigational vaccine targeting pathological tau proteins, in adults aged 65 to 80 years with preclinical Alzheimers disease. This Phase 1, randomized, double-blind, placebo-controlled study aims to assess the safety, tolerability, and immune response elicited by the vaccine in cognitively unimpaired participants who have biomarker evidence of early Alzheimers pathology. Participants will be randomly assigned in a 31 ratio to receive one of three ascending doses of AV-1980R 20 g, 60 g, or 180 g or placebo. The vaccine or placebo is given as three intramuscular injections at Weeks 0, 4, and 38. The study includes follow-up visits through Week 58 to monitor participants. During the study, participants will undergo safety assessments including monitoring for adverse events, vital signs, ECG, laboratory tests, neurological exams, and brain MRI scans. Researchers will measure immune responses such as anti-tau antibody levels and T-cell activity, along with exploratory evaluations of plasma Alzheimers biomarkers, tau PET imaging, and cognitive function. The total participation period spans from screening through Week 58, focusing on vaccine safety and immune effects.

Age: 65Years - 80YearsAll GendersPhase 1
6 locations

1-10 of 24

1